Claris Advisors’s Biogen BIIB Stock Holding History

Claris Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11	Closed	-$2.13K	–	197
2024 Q3	$2.13K	Buy	+11	New	+$2.3K	﹤0.01%	327

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Claris Advisors's BIIB Position: Q4 2024 in Review

Claris Advisors sold out of Biogen (BIIB) in Q4 2024, closing a stake of 11 shares — an estimated $2.13K sold.

Claris Advisors first reported a position in BIIB in Q3 2024 and held it in 1 quarter. The position peaked at $2.13K in Q3 2024. 876 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

Claris Advisors reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
Claris Advisors sold 11 Biogen shares in Q4 2024, an estimated $2.13K.
Claris Advisors first reported a position in Biogen in Q3 2024 and held it in 1 quarter.
Claris Advisors's Biogen position peaked at $2.13K in Q3 2024.
876 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on Claris Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.